Who are Tetrandrine Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cleviprex, Sular, Norvasc, Plendil, Dynacirc, Nimotop.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tetrandrine-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Tetrandrine Tablets — Competitive Intelligence Brief

Tetrandrine Tablets (Tetrandrine Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker; immunosuppressive agent. Area: Immunology; Rheumatology; Pulmonology.

marketed Calcium channel blocker; immunosuppressive agent L-type and T-type calcium channels Immunology; Rheumatology; Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Tetrandrine Tablets (Tetrandrine Tablets) — Peking University Third Hospital. Tetrandrine is a bisbenzylisoquinoline alkaloid that blocks calcium channels and modulates immune responses, primarily used as an anti-inflammatory and immunosuppressive agent.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tetrandrine Tablets TARGET	Tetrandrine Tablets	Peking University Third Hospital	marketed	Calcium channel blocker; immunosuppressive agent	L-type and T-type calcium channels
Cleviprex	CLEVIDIPINE	Chiesi	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	2008-01-01
Sular	NISOLDIPINE	Azurity	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1995-01-01
Norvasc	amlodipine	Pfizer Inc.	marketed	Calcium channel blocker (dihydropyridine)	Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6	1992-07-31
Plendil	FELODIPINE	AstraZeneca	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent T-type calcium channel subunit alpha-1H	1991-01-01
Dynacirc	ISRADIPINE	Smithkline Beecham	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1D	1990-01-01
Nimotop	NIMODIPINE		marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1F	1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker; immunosuppressive agent class)

Peking University Third Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tetrandrine Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/tetrandrine-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab